Webb27 mars 2024 · Eligible patients with primary advanced stage III or IV or first recurrent endometrial cancer were randomly assigned in a 1:1 ratio to receive either dostarlimab … Webb27 mars 2024 · RUBY is a two-part global, randomised, double-blind, multicentre phase III trial of patients with primary advanced or recurrent endometrial cancer. Part 1 is evaluating dostarlimab plus...
Results from Astellas’ Phase 3 SPOTLIGHT Trial of Investigational ...
Webb27 mars 2024 · RUBY is a two-part global, randomized, double-blind, multicenter phase III trial of patients with primary advanced or recurrent endometrial cancer. Part 1 is evaluating dostarlimab-gxly... Webb5 dec. 2024 · RUBY is a two-part global, randomised, double-blind, multicentre phase III trial of patients with primary advanced or recurrent endometrial cancer. Part 1 is evaluating dostarlimab plus carboplatin-paclitaxel followed by dostarlimab versus carboplatin-paclitaxel plus placebo followed by placebo. risk of rain 2 crystal burden
GSK plc - Phase III RUBY clinical trial demonstrates potential of ...
Webb10 apr. 2024 · Exa-cel is currently undergoing two Phase III trials, CLIMB-111 and CLIMB-121, ... as it initiates parallel patient dosing for SCD in the Phase I/II RUBY trial and doses the first patient for TDT in the Phase I/II EDITHAL trial. Updates for RUBY are expected by mid-2024 and data from EDITHAL will be available by the end of 2024. Webb30 mars 2024 · Phase III RUBY clinical trial demonstrates potential of Jemperli + chemotherapy to redefine the treatment of primary advanced or recurrent endometrial … Webb27 juli 2024 · Finally, preliminary results of a Phase Ia study of Atezolizumab (NCT01375842) monotherapy in relapsed endometrial cancer were reported as abstract at ASCO 2024. Fifteen patients were evaluated for safety and efficacy with a minimum follow-up of 11.2 months. No G4-5 related AEs occurred. Regarding efficacy ORR was 13% … smh what does it mean in text